Terms: = Leukemia AND REL, I-Rel, 5966, ENSG00000162924, C-Rel
222 results:
1. The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature.
Mathioudaki A; Wang X; Sedloev D; Huth R; Kamal A; Hundemer M; Liu Y; Vasileiou S; Lulla P; Müller-Tidow C; Dreger P; Luft T; Sauer T; Schmitt M; Zaugg JB; Pabst C
Blood; 2024 Mar; 143(13):1269-1281. PubMed ID: 38197505
[TBL] [Abstract] [Full Text] [Related]
2. Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation.
Spyridonidis A; Labopin M; Gedde-Dahl T; Ganser A; Stelljes M; Craddock C; Wagner-Drouet EM; Versluis J; Schroeder T; Blau IW; Wulf GG; Dreger P; Olesen G; Sengeloev H; Kröger N; Potter V; Forcade E; Passweg J; de Latour RP; Maertens J; Wilson KMO; Bourhis JH; Finke J; Brissot E; Bazarbachi A; Giebel S; Savani BP; Nagler A; Ciceri F; Mohty M
Bone Marrow Transplant; 2024 Feb; 59(2):217-223. PubMed ID: 37978322
[TBL] [Abstract] [Full Text] [Related]
3. Clonal evolution dissection reveals that a high MSI2 level promotes chemoresistance in T-cell acute lymphoblastic leukemia.
Zhang J; Duan Y; Wu P; Chang Y; Wang Y; Hu T; Liu C; Chen X; Zong S; Chen X; Wu Y; Jin L; Lan Y; Liu X; Cheng X; Ding F; Li T; Chen X; Guo Y; Chen Y; Yang W; Zhang L; Zou Y; Cheng T; Zhu X; Zhang Y
Blood; 2024 Jan; 143(4):320-335. PubMed ID: 37801708
[TBL] [Abstract] [Full Text] [Related]
4. Conferone, a coumarin from
Rafatpanah H; Golizadeh M; Mahdifar M; Mahdavi S; Iranshahi M; Rassouli FB
Int J Immunopathol Pharmacol; 2023; 37():3946320231197592. PubMed ID: 37688389
[TBL] [Abstract] [Full Text] [Related]
5. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.
Russler-Germain DA; Krysiak K; Ramirez C; Mosior M; Watkins MP; Gomez F; Skidmore ZL; Trani L; Gao F; Geyer S; Cashen AF; Mehta-Shah N; Kahl BS; Bartlett NL; Alderuccio JP; Lossos IS; Ondrejka SL; Hsi ED; Martin P; Leonard JP; Griffith M; Griffith OL; Fehniger TA
Blood Adv; 2023 Sep; 7(18):5524-5539. PubMed ID: 37493986
[TBL] [Abstract] [Full Text] [Related]
6. Quality-adjusted survival time without symptoms or toxicity of acalabrutinib with or without obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia.
Sharman JP; Miranda P; Roos J; Emeribe U; Cai L; Liljas B; Gaitonde P
Leuk Lymphoma; 2023; 64(7):1243-1252. PubMed ID: 37221877
[TBL] [Abstract] [Full Text] [Related]
7. Refining prognosis in chronic lymphocytic leukemia with normal Fluorescence in situ hybridization results.
Avenarius MR; Huang Y; Hyak J; Byrd JC; Bhat SA; Grever M; Kittai AS; Rogers KA; Jones D; Zhao W; Heerema NA; Abruzzo LV; Woyach J; Miller CR
Hematol Oncol; 2023 Oct; 41(4):771-775. PubMed ID: 37010242
[TBL] [Abstract] [Full Text] [Related]
8. Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma.
Furqan F; Ahn KW; Chen Y; Kaur M; Abutalib SA; Ahmed N; Ahmed S; Kharfan-Dabaja MA; Friedberg J; Gregory T; Hill L; Sterling C; Barta SK; Shadman M; Perales MA; Zain J; Herrera AF; Sauter C; Hamadani M
Br J Haematol; 2023 Jan; 200(1):54-63. PubMed ID: 36120837
[TBL] [Abstract] [Full Text] [Related]
9. Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia.
Ramos-Muntada M; Trincado JL; Blanco J; Bueno C; Rodríguez-Cortez VC; Bataller A; López-Millán B; Schwab C; Ortega M; Velasco P; Blanco ML; Nomdedeu J; Ramírez-Orellana M; Minguela A; Fuster JL; Cuatrecasas E; Camós M; Ballerini P; Escherich G; Boer J; DenBoer M; Hernández-Rivas JM; Calasanz MJ; Cazzaniga G; Harrison CJ; Menéndez P; Molina O
Mol Oncol; 2022 Aug; 16(16):2899-2919. PubMed ID: 35726693
[TBL] [Abstract] [Full Text] [Related]
10. Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for relapsed/Refractory Acute Myeloid leukemia: An ALWP/EBMT Analysis.
Nagler A; Ngoya M; Galimard JE; Labopin M; Bornhäuser M; Stelljes M; Finke J; Ganser A; Einsele H; Kröger N; Brecht A; Bethge W; Edinger M; Kulagin A; Passweg J; Blau IW; Elmaagacli A; Schäfer-Eckart K; Platzbecker U; Schroeder T; Bunjes D; Tischer J; Martin S; Spyridonidis A; Giebel S; Savani B; Mohty M
Clin Cancer Res; 2022 Oct; 28(19):4258-4266. PubMed ID: 35670780
[TBL] [Abstract] [Full Text] [Related]
11. An alternative CYB5A transcript is expressed in aneuploid ALL and enriched in relapse.
Bartsch L; Schroeder MP; Hänzelmann S; Bastian L; Lázaro-Navarro J; Schlee C; Tanchez JO; Schulze V; Isaakidis K; Rieger MA; Gökbuget N; Eckert C; Serve H; Horstmann M; Schrappe M; Brüggemann M; Baldus CD; Neumann M
BMC Genom Data; 2022 Apr; 23(1):30. PubMed ID: 35436854
[TBL] [Abstract] [Full Text] [Related]
12. Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL.
Kameda K; Kako S; Kim SW; Usui Y; Kato K; Fukuda T; Uchida N; Kobayashi H; Wakayama T; Sakaida E; Yano S; Imada K; Nara M; Ikeda T; Fuchida SI; Ishikawa J; Sugahara H; Kanda J; Kimura T; Ichinohe T; Atsuta Y; Kondo E
Leukemia; 2022 May; 36(5):1361-1370. PubMed ID: 35347237
[TBL] [Abstract] [Full Text] [Related]
13. A novel approach for relapsed/refractory FLT3
Li KX; Wu HY; Pan WY; Guo MQ; Qiu DZ; He YJ; Li YH; Yang DH; Huang YX
Mol Cancer; 2022 Mar; 21(1):66. PubMed ID: 35246156
[TBL] [Abstract] [Full Text] [Related]
14. Whole-genome landscape of adult T-cell leukemia/lymphoma.
Kogure Y; Kameda T; Koya J; Yoshimitsu M; Nosaka K; Yasunaga JI; Imaizumi Y; Watanabe M; Saito Y; Ito Y; McClure MB; Tabata M; Shingaki S; Yoshifuji K; Chiba K; Okada A; Kakiuchi N; Nannya Y; Kamiunten A; Tahira Y; Akizuki K; Sekine M; Shide K; Hidaka T; Kubuki Y; Kitanaka A; Hidaka M; Nakano N; Utsunomiya A; Sica RA; Acuna-Villaorduna A; Janakiram M; Shah U; Ramos JC; Shibata T; Takeuchi K; Takaori-Kondo A; Miyazaki Y; Matsuoka M; Ishitsuka K; Shiraishi Y; Miyano S; Ogawa S; Ye BH; Shimoda K; Kataoka K
Blood; 2022 Feb; 139(7):967-982. PubMed ID: 34695199
[TBL] [Abstract] [Full Text] [Related]
15. Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML.
Cortes JE; Lin TL; Uy GL; Ryan RJ; Faderl S; Lancet JE
J Hematol Oncol; 2021 Jul; 14(1):110. PubMed ID: 34256819
[TBL] [Abstract] [Full Text] [Related]
16. Validation of the "fitness criteria" for the treatment of older patients with acute myeloid leukemia: A multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (rel).
Borlenghi E; Pagani C; Zappasodi P; Bernardi M; Basilico C; Cairoli R; Fracchiolla N; Todisco E; Turrini M; Cattaneo C; Da Vià M; Ciceri F; Passamonti F; Mancini V; Sciumè M; Cerqui E; Sciumè M; Rossi G
J Geriatr Oncol; 2021 May; 12(4):550-556. PubMed ID: 33097455
[TBL] [Abstract] [Full Text] [Related]
17. The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia: On behalf of the acute leukemia working party (ALWP) of the European group for blood and marrow transplantation (EBMT).
Poiani M; Labopin M; Battipaglia G; Beelen DW; Tischer J; Finke J; Brecht A; Forcade E; Ganser A; Passweg JR; Labussiere-Wallet H; Yakoub-Agha I; Schäfer-Eckart K; Kroeger N; Guffroy B; Ruggeri A; Esteve J; Nagler A; Mohty M
Am J Hematol; 2021 Jan; 96(1):40-50. PubMed ID: 32944990
[TBL] [Abstract] [Full Text] [Related]
18. Genome-Wide Association Study of Susceptibility Loci for TCF3-PBX1 Acute Lymphoblastic leukemia in Children.
Lee SHR; Qian M; Yang W; Diedrich JD; Raetz E; Yang W; Dong Q; Devidas M; Pei D; Yeoh A; Cheng C; Pui CH; Evans WE; Mullighan CG; Hunger SP; Savic D; Relling MV; Loh ML; Yang JJ
J Natl Cancer Inst; 2021 Jul; 113(7):933-937. PubMed ID: 32882024
[TBL] [Abstract] [Full Text] [Related]
19. A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy.
Solem CT; Bell TJ; Kwon Y; Cappelleri JC; Johnson C; Bhattacharyya H; Hoang CJ; Cortes JE
Cancer; 2020 Oct; 126(19):4315-4321. PubMed ID: 32697335
[TBL] [Abstract] [Full Text] [Related]
20. The c-rel-c-Myc axis controls metabolism and proliferation of human T leukemia cells.
Li X; Luo G; Li T; Sun H; Wang W; Eiler E; Goldsmith JR; Chen YH
Mol Immunol; 2020 Sep; 125():115-122. PubMed ID: 32659596
[TBL] [Abstract] [Full Text] [Related]
[Next]
